Alliancebernstein L.P. Pyxis Oncology, Inc. Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 13,470 shares of PYXS stock, worth $16,972. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,470
Previous 13,470
-0.0%
Holding current value
$16,972
Previous $49,000
59.18%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
107Shares Held
28.7MCall Options Held
658KPut Options Held
54.1K-
Laurion Capital Management LP New York, NY3.63MShares$4.57 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$3.08 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$2.4 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY1.13MShares$1.42 Million1.36% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $44.2M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...